Trials / Completed
CompletedNCT00298870
Randomized Trial for Pharmacogenomics-based Tuberculosis Therapy (RT-PGTT)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 172 (actual)
- Sponsor
- Osaka University · Academic / Other
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to elucidate whether the individualized medicine based on NAT2 gene polymorphism could improve the safety, efficacy and economical benefits of multi-drug therapy for the pulmonary tuberculosis with isoniazid.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Isoniazid | Modified daily isoniazid dose : approx. 7.5 mg/kg, 5 mg/kg and 2.5 mg/kg for rapid, intermediate and slow acetylators, respectively |
| DRUG | isoniazed | Conventional standard daily isoniazid dose : approx. 5 mg/kg b.w. for all |
Timeline
- Start date
- 2005-06-01
- First posted
- 2006-03-03
- Last updated
- 2012-10-18
Locations
4 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00298870. Inclusion in this directory is not an endorsement.